Natural Killer (NK) Cell Therapeutics Market Size to Reach $5.09 Billion Globally by 2026 Rising Industry with prevalence of cancer, gastrointestinal diseases, and others.

12 Aug 2021
www.biospace.com
AntibodyCell TherapyImmunotherapyAcquisitionCollaborate
Rise in use of NK cells for the treatment of infections & liver diseases, surge in awareness among the population regarding various immunotherapies, and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells drive the growth of the global NK cell therapeutics market. "Natural Killer Cell Therapeutics Market by Therapeutics, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2018–2026." The report provides a detailed analysis of the drivers & opportunities, changing market trends, competitive market landscape, and market size & estimates. According to the report, the global NK Cell Therapeutics market was projected at $1.40 billion in 2018 and is expected to hit $5.09 billion by 2026, registering a CAGR of 17.4% during 2019–2026. Rise in use of NK cells for the treatment of infections & liver diseases, surge in awareness among the population regarding various immunotherapies, and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the growth of the global NK cell therapeutics market. On the other hand, lack of specificity & poor in-vivo survival of the cells, higher costs associated with the therapies, and their adverse side effects restrain the growth of the market to some extent. However, significant surge in R&D activities toward development of immunotherapy in developing economies is anticipated to create lucrative opportunities in the near future. Request for Sample Report for More Insights@ The NK cell-directed antibodies segment to lead the trail till 2026 Based on therapeutics, the NK cell-directed antibodies segment accounted for nearly three-fifths of the total market share in 2018 and is anticipated to rule the roost during the estimated period. Increase in usage of monoclonal antibodies for the treatment of various diseases and its easy availability spur the growth. At the same time, the NK cell therapies segment would grow at the fastest CAGR of 17.6% till 2026. Extensive research in developing NK cell therapeutics to treat cancer is the major factor driving the growth. The cancer segment generated the highest growth in 2019- Based on application, the cancer segment contributed to more than three-fourths of the total market revenue in 2018 and is expected to dominate through 2019–2026. This is attributed to significant increase in the prevalence of cancer in this region. The gastrointestinal diseases segment, on the other hand, is projected to grow at the fastest CAGR of 19.3% during the forecast period. This is attributed to the rising growth in geriatric population, and improvement in healthcare facilities in the province. North America to be dominant by 2026- Based on geography, North America held the major share in 2018, accounting for nearly half of the total market. Surge in the incidence of cancer in the region has driven the growth. At the same time, the Asia-Pacific region is predicted to showcase the fastest CAGR of 19.5% throughout the study period. Frontrunners in the industry- The key market players analyzed in the report include Affimed N.V., Altor BioScience Corporation, Chipscreen Biosciences, Ltd., NKT Therapeutics, Inc., Innate Pharma S.A., Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited, and others. Incorporating a number of high-end strategies including expansions, mergers & acquisitions, partnerships, joint ventures, collaborations, and others, these market players have become able to heighten their stand in the industry. Key Market Segments: By Therapeutics:- NK Cell Therapies NK Cell Directed Antibodies By Application:- Cancer Gastrointestinal Diseases Immunoproliferative Disorders Others By End User:- Research Centers & Institutes Hospitals Others By Region:- North America Europe Asia-Pacific Trending Reports of Healthcare: Biologics Market - Global Opportunity Analysis and Industry Forecast, 2019-2028 Compression Therapy Market - Global Opportunity Analysis and Industry Forecast, 2019-2028 About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch (dot) com
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.